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Radiogenomics is the whole genome application of radiogenetics, 
which studies the influence of genetic variation on radiation response. 
Work in the area focuses on uncovering the underlying common 
genetic causes of individual variation in sensitivity to radiation, which 
is important for effective, safe treatment. Many radiogenomics 
studies published to-date, have used a candidate gene approach; i.e. 
genes thought to be involved in radiotherapy toxicity are studied. 
Such genetic associations have proved difficult to replicate. More 
recently studies have used a genome-wide approach, where the whole 
genome is screened for genetic variations associated with 
radiotherapy toxicity. GWAS studies of radiotherapy toxicity have 
shown evidence that genetic variations that are associated with late 
radiotherapy toxicity exist. Power calculations from such GWAS 
suggest that future studies should include more than 2500 
participants. Meta-analysis of GWAS studies in the radiogenomics 
consortium is currently underway to achieve such numbers. Continuing 
recruitment of patients into studies within the Radiogenomics 
Consortium is essential so that sufficiently powered studies can be 
performed, and methodological challenges addressed. 
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Purpose/Objective: Parametrial boost (PB) is used in advanced cancer 
cervix to increase the dose in regions where contribution from 
intracavitary brachytherapy (IC BT) is insufficient. Midline block is 
then used to protect midline organs at risk (OAR). However as stated 
by IAEA (2010), the efficacy of parametrial boosts has not been 
systematically tested and there is little literature evidence to support 
its routine use. 
An alternative technique for parametrial boosting is the combined 
intracavitary and interstitial (IC/IS) BT. The purpose of our study is to 
evaluate the dose delivered by IC BT and PB and compare it to IC/IS 
BT.  
Materials and Methods: We evaluated 51 consecutive patients with 
parametrial involvement at diagnosis. At BT 23 patients had persistent 
parametrial involvement necessitating combined IC/IS BT. For the 23 
patients we compared optimised IC BT combined with external beam 
PB field to the delivered optimised IC/IS BT. Whole pelvis conformal 
EBRT 45-50 Gy /25-30 fx and PDR BT 15-17.5 Gy x 2fx IC/IS was 
delivered. PB field was created as an external beam AP/PA field of 9 
Gy / 5fx, with midline block conformed to the isodose line 85 Gy and 
of at least 4 cm width. For the PB scenario summation of doses from 
EBRT plus an optimised IC BT plan and PB fields were used. The 
physical 3D dose distribution was converted to the EQD2 using α/β = 
10 Gy for tumour, and = 3 Gy for OAR with T½ = 1.5 hr. DVH 
parameters obtained in total EQD2 were GTV, HR CTV, IR CTV: D90, 
D100 and D2cm3for rectum, bladder, sigmoid and bowel. 
Testing the impact of organ movement was done by shaking the EQD2 
dose map 1 cm bilaterally and reading out the DVH parameters. 
The normal tissue volume irradiated to 60 Gy EQD2 (total EBRT+BT) 
was measured.  
Results: Table 1 shows mean total EQD2+SD (Gy) of IC+PB versus IC/IS 
BT. With IC+PB, 3 patients had < 79 Gy to the HR CTV D90 while IC/IS 
resulted in doses >84Gy for all patients. Comparing the target dose 
delivered by the shifted dose map to PB resulted in a difference of 1.0 
± 1.8 Gy for HR CTV D90, and - 1.0 ± 1.8 Gy for IR CTV D90. OAR D2cm3 
changed by 0.8 ± 1.3 Gy, 0.7 ± 1.0, 0.4 ± 2.6 Gy and 0.1 ± 2.8 Gy for 
bladder, rectum, sigmoid and bowel respectively. 
The PB resulted in a significantly higher V60 as compared to the IC/IS: 
For the IC/IS technique the mean V60 was 228.4 ± 81.5 cm3 and for 
the IC + PB it was 593.5 ±595.6 cm3 (p= 0.004). 
 
  
Conclusions: Midline blocked fields significantly increases dose by 5-9 
Gy to the D2cm3 of the rectum, sigmoid, bladder and bowel as 
compared to IC/IS, but was robust in terms DVH parameters for the 
'shaked' EQD2 dose map. Mean HR CTV D90 were comparable for both 
techniques, however PB resulted in significant underdosage for 3 
cases. With EBRT PB, large volume is irradiated to at least 60 Gy 
which may result in increased clinical morbidity expressed by this 
irradiated bowel and normal tissue. IC/IS compared to IC + PB spares 
better the OAR and deliver a more conformed RT to the targeted area 
with less normal tissue volume receiving 60Gy. 
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Purpose/Objective: In radiotherapy for cervix cancer elective and 
pathological lymph nodes (LN) in the pelvis, abdomen and inguinal 
regions are irradiated to a certain dose during external beam 
radiotherapy (EBRT).  
However the LNs will also receive a fraction of dose during 
brachytherapy (BT).  
This study aims to 1) evaluate the BT dose contribution to LN groups, 
2) compare LN doses from standard non-optimised PDRBT and 
optimised MRI guided PDR BT. 
Materials and Methods: 25 consecutive patients who received whole 
pelvis 3D conformal EBRT (45-50Gy in 25 or 30 fractions) and 2 
fractions of MRI guided PDR BT (each 15 or 17.5Gy) were analysed. LN 
groups were delineated as follows: para-aortic (PAN), common (CI), 
external (EI) and internal (II) iliac, obturator (OB), inguinal (ING), and 
presacral (PS). For each group D98%, D50% and D2% for full optimised 
BT were compared to those forstandard non-optimised BT. BT dose 
was normalised to a 2Gy fraction size (EQD2) using the linear 
quadratic model (α/β=10Gy, T1/2=1.5h). Correlation between TRAK 
and dose was assessed for all LNs with linear regression. 
Results: As shown in table 1 BT contributed with considerable dose 
(mean D50% was 3.8-6.2Gy) to the pelvic LNs (EI, II, OB, PS) in 
optimised plans. Less dose contribution was seen in CI, PAN (mean 
D50% was 0.5-1.9 Gy) and ING (1.5 Gy). Large inter-patient variation 
was seen with SDs of up to 2.6 Gyof D50%. For non-optimised BT D50% 
doses to PAN, CI and ING ranged from 0.6 to 2.7 Gy and to pelvic LN it 
ranged from 4.1 to 6.4 Gy.As shown in Table 1, a generally smaller 
dose to different LN-stations was delivered by the optimised plan 
compared to the standard plan. This is compatible to the efforts of 
creating a more conformal BT with dose optimisation. However, 
although differences were statistically significant for most LNs, they 
only amounted toa mean of 0.2 - 0.9 Gy (D50%). This difference can 
be explained by the overall reduction of the TRAK in the optimised 
plan by 0.25cGy±0.3 (p=0.0005) compared to the standard BT plan. 
This also explains the higher dose reduction (appr25%) to the 
abdominal LN group, compared to the LN dose reduction in the pelvic 
area close to HR - CTV (appr 10%). The dwell positions in the tip of the 
tandem are not used to the same degree in the optimised plan as in 
the standard plan,where all the positions are equally loaded. 
